|

Ribupatide Clinical Trials

3 actively recruiting trials across 3 locations

▲ +2 trials since July 2026

Also known as: KAI-9531

Pipeline

Phase 3: 3

Top Sponsors

  • Kailera3

Indications

  • Diabetes3
  • Obesity2
  • Overweight With Diabetes1
  • Obesity With Diabetes1
  • Overweight1

Anniston, Alabama1 trial

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Kailera Clinical Site

Phase 3

Cullman, Alabama1 trial

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Kailera Clinical Site

Phase 3

Glendale, Arizona1 trial

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Kailera Clinical Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.